MX2015016077A - Esteronitronas para el tratamiento y prevencion de ictus o isquemia cerebral, enfermedades de alzheimer, parkinson y esclerosis lateral amiotrofica. - Google Patents

Esteronitronas para el tratamiento y prevencion de ictus o isquemia cerebral, enfermedades de alzheimer, parkinson y esclerosis lateral amiotrofica.

Info

Publication number
MX2015016077A
MX2015016077A MX2015016077A MX2015016077A MX2015016077A MX 2015016077 A MX2015016077 A MX 2015016077A MX 2015016077 A MX2015016077 A MX 2015016077A MX 2015016077 A MX2015016077 A MX 2015016077A MX 2015016077 A MX2015016077 A MX 2015016077A
Authority
MX
Mexico
Prior art keywords
ischaemia
alzheimer
treatment
lateral sclerosis
amyotrophic lateral
Prior art date
Application number
MX2015016077A
Other languages
English (en)
Other versions
MX370402B (es
Inventor
José Luis Marco Contelles
Alberto Alcázar González
Original Assignee
Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal filed Critical Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal
Publication of MX2015016077A publication Critical patent/MX2015016077A/es
Publication of MX370402B publication Critical patent/MX370402B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Esteronitronas con alta permeabilidad a la barrera hematoencefálica, capacidad antioxidante, y neuroprotectora, como potenciales fármacos para el tratamiento de del ictus o isquemia cerebral, enfermedades de Alzheimer, Parkinson y esclerosis lateral amiotrófica.
MX2015016077A 2013-05-22 2014-05-22 Esteronitronas para el tratamiento y prevencion del ictus o isquemia cerebral, enfermedades de alzheimer, parkinson y esclerosis lateral amiotrofica. MX370402B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201330738A ES2525503B1 (es) 2013-05-22 2013-05-22 Uso de esteronitronas para el tratamiento y prevención del ictus o accidente cerebrovascular, enfermedades de alzheimer, parkinson y esclerosis lateral amiotrófica
PCT/ES2014/070421 WO2014188046A1 (es) 2013-05-22 2014-05-22 Esteronitronas para el tratamiento y prevención del ictus o isquemia cerebral, enfermedades de alzheimer, parkinson y esclerosis lateral amiotrófica

Publications (2)

Publication Number Publication Date
MX2015016077A true MX2015016077A (es) 2016-03-21
MX370402B MX370402B (es) 2019-12-11

Family

ID=51938998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016077A MX370402B (es) 2013-05-22 2014-05-22 Esteronitronas para el tratamiento y prevencion del ictus o isquemia cerebral, enfermedades de alzheimer, parkinson y esclerosis lateral amiotrofica.

Country Status (15)

Country Link
US (1) US10071106B2 (es)
EP (1) EP3000469B1 (es)
JP (1) JP6424212B2 (es)
CN (1) CN105377264B (es)
AU (1) AU2014270269B2 (es)
BR (1) BR112015029302A2 (es)
CA (1) CA2913182A1 (es)
ES (2) ES2525503B1 (es)
IT (1) ITRM20140075U1 (es)
MX (1) MX370402B (es)
PL (1) PL3000469T3 (es)
PT (1) PT3000469T (es)
RU (1) RU2668514C2 (es)
TR (1) TR201908363T4 (es)
WO (1) WO2014188046A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3875095A1 (en) * 2020-03-05 2021-09-08 Isquaemia Biotech, S.L. Steroidal nitrone for the treatment and/or prevention of a cerebral stroke or ischaemia
CN112494491B (zh) * 2020-12-14 2022-04-01 东北大学 克班宁在制备预防或治疗神经退行性疾病的药物中的用途
CN113304129B (zh) * 2021-06-16 2022-11-08 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 单烯酮类单羰基姜黄素类似物在制备抗氧化药物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU491625A1 (ru) * 1973-11-15 1975-11-15 Институт Органической Химии Им.Н.Д. Зелинского Способ получени изоксазолидино-(16альфа,17альфа-d)-стероидов
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
ES2395803B1 (es) * 2011-08-01 2013-12-19 Consejo Superior De Investigaciones Científicas (Csic) - 80% Quinolilnitronas

Also Published As

Publication number Publication date
ES2525503B1 (es) 2015-10-15
ES2730963T3 (es) 2019-11-13
CA2913182A1 (en) 2014-11-27
WO2014188046A1 (es) 2014-11-27
BR112015029302A2 (pt) 2017-07-25
ES2525503A1 (es) 2014-12-23
JP6424212B2 (ja) 2018-11-14
JP2016524610A (ja) 2016-08-18
RU2015154103A (ru) 2017-06-27
US20160089382A1 (en) 2016-03-31
EP3000469A1 (en) 2016-03-30
PT3000469T (pt) 2019-06-14
PL3000469T3 (pl) 2019-10-31
CN105377264A (zh) 2016-03-02
CN105377264B (zh) 2019-02-15
ITRM20140075U1 (it) 2015-11-16
AU2014270269B2 (en) 2018-05-17
US10071106B2 (en) 2018-09-11
EP3000469B1 (en) 2019-03-13
AU2014270269A1 (en) 2015-12-10
MX370402B (es) 2019-12-11
RU2668514C2 (ru) 2018-10-01
TR201908363T4 (tr) 2019-06-21
EP3000469A4 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
IN2014MN02236A (es)
ECSP16070327A (es) Heteroaril amidas como inhibidores de agregación de proteína
JO3316B1 (ar) مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EP3039139A4 (en) Engineered primate l-methioninase for therapeutic purposes
IL243572B (en) Drug combination for the treatment of melanoma
PH12014502032A1 (en) Treatment of brain cancer
IL241175A0 (en) A pharmaceutical preparation for the treatment of fungal infections
IN2013MU03918A (es)
MX2018000093A (es) Uso de cepas de microbacterium para la produccion de agentes antibacterianos.
SG10201705899XA (en) Prevention & treatment of neuropathy
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
HK1223632A1 (zh) 靶向的酶化合物及其用途
TN2016000213A1 (en) A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder.
MX370402B (es) Esteronitronas para el tratamiento y prevencion del ictus o isquemia cerebral, enfermedades de alzheimer, parkinson y esclerosis lateral amiotrofica.
EP2991733A4 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
WO2014056779A8 (de) Arzneimittel zur prophylaxe und behandlung einer neurodegenerativen erkrankung
IN2013MU03317A (es)
IN2014DN07989A (es)
IN2013MU02469A (es)
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
IN2013MU02509A (es)
IN2013MU03801A (es)
IN2013CH02437A (es)
AU2015901877A0 (en) Treatment of amyotrophic lateral sclerosis
IN2013MU02508A (es)

Legal Events

Date Code Title Description
FG Grant or registration